T F Ulmer1, C de Jong2, A Andert3, P Bruners3, C M Heidenhain4, W Schoening3, M Schmeding3, U P Neumann3. 1. Department of General, Visceral and Transplantation Surgery, University Hospital of the RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Germany. f.ulmer@ukaachen.de. 2. Department of Diagnostic and Interventional Radiology, University Hospital of the RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Germany. 3. Department of General, Visceral and Transplantation Surgery, University Hospital of the RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Germany. 4. Department of General and Visceral Surgery, Sana Hospital Gerresheim, Graeulingerstr. 120, 40625, Duesseldorf, Germany.
Abstract
BACKGROUND: The main limiting factor for major liver resections is the volume and function of the future remnant liver (FLR). Portal vein embolization (PVE) is now standard in most centers for preoperative hypertrophy of FLR. However, it has a failure rate of about 20-30 %. In these cases, the "Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy" (ALPPS) may represent a suitable and possibly the only alternative. METHODS: We performed a retrospective analysis of nine patients who had ALPPS following an insufficient hypertrophy after PVE. Computed tomography volumetry were performed before and after PVE as well as the first step of ALPPS. Furthermore, complications, 30-day mortality and outcome were analyzed. RESULTS: The FLR volume rose significantly by 77.7 ± 40.7 % (FLR/TLV: 34.9 ± 9.7 %) as early as 9 days after the first stage despite insufficient hypertrophy after preoperative portal vein embolization. Major complications (Grade > IIIb) occurred in 33 % of the patients, and 30-day mortality was 11.1 %. The OS at 1 and 2 years was 78 and 44 %. Four patients are presently still alive at a median of 33.4 (range 15-48) months (survival rate 44.4 %). CONCLUSION: The ALPPS procedure could be a suitable alternative for patients following insufficient PVE or indeed the last chance of a potentially curative treatment in this situation. Nevertheless, the high morbidity and mortality rates and the lack of data on the long-term oncological outcome must also be taken into account.
BACKGROUND: The main limiting factor for major liver resections is the volume and function of the future remnant liver (FLR). Portal vein embolization (PVE) is now standard in most centers for preoperative hypertrophy of FLR. However, it has a failure rate of about 20-30 %. In these cases, the "Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy" (ALPPS) may represent a suitable and possibly the only alternative. METHODS: We performed a retrospective analysis of nine patients who had ALPPS following an insufficient hypertrophy after PVE. Computed tomography volumetry were performed before and after PVE as well as the first step of ALPPS. Furthermore, complications, 30-day mortality and outcome were analyzed. RESULTS: The FLR volume rose significantly by 77.7 ± 40.7 % (FLR/TLV: 34.9 ± 9.7 %) as early as 9 days after the first stage despite insufficient hypertrophy after preoperative portal vein embolization. Major complications (Grade > IIIb) occurred in 33 % of the patients, and 30-day mortality was 11.1 %. The OS at 1 and 2 years was 78 and 44 %. Four patients are presently still alive at a median of 33.4 (range 15-48) months (survival rate 44.4 %). CONCLUSION: The ALPPS procedure could be a suitable alternative for patients following insufficient PVE or indeed the last chance of a potentially curative treatment in this situation. Nevertheless, the high morbidity and mortality rates and the lack of data on the long-term oncological outcome must also be taken into account.
Authors: Erik Schadde; Victoria Ardiles; Ricardo Robles-Campos; Massimo Malago; Marcel Machado; Roberto Hernandez-Alejandro; Olivier Soubrane; Andreas A Schnitzbauer; Dimitri Raptis; Christoph Tschuor; Henrik Petrowsky; Eduardo De Santibanes; Pierre-Alain Clavien Journal: Ann Surg Date: 2014-11 Impact factor: 12.969
Authors: Andreas A Schnitzbauer; Sven A Lang; Holger Goessmann; Silvio Nadalin; Janine Baumgart; Stefan A Farkas; Stefan Fichtner-Feigl; Thomas Lorf; Armin Goralcyk; Rüdiger Hörbelt; Alexander Kroemer; Martin Loss; Petra Rümmele; Marcus N Scherer; Winfried Padberg; Alfred Königsrainer; Hauke Lang; Aiman Obed; Hans J Schlitt Journal: Ann Surg Date: 2012-03 Impact factor: 12.969
Authors: D A Wicherts; R J de Haas; P Andreani; D Sotirov; C Salloum; D Castaing; R Adam; D Azoulay Journal: Br J Surg Date: 2010-02 Impact factor: 6.939
Authors: Joost R van der Vorst; Ronald M van Dam; Rogier S A van Stiphout; Maartje A van den Broek; Ilona H Hollander; Alfons G H Kessels; Cornelis H C Dejong Journal: World J Surg Date: 2010-10 Impact factor: 3.352
Authors: Dimitrios Moris; Sean Ronnekleiv-Kelly; Ioannis D Kostakis; Diamantis I Tsilimigras; Eliza W Beal; Alexandros Papalampros; Dimitrios Dimitroulis; Evangelos Felekouras; Timothy M Pawlik Journal: World J Surg Date: 2018-03 Impact factor: 3.352
Authors: Resmi A Charalel; Jeffrey Sung; Gulce Askin; Jonathan Jo; Maria Mitry; Caroline Chung; Lyubov Tmanova; David C Madoff Journal: Curr Oncol Rep Date: 2021-10-30 Impact factor: 5.075
Authors: Jan Bednarsch; Zoltan Czigany; Samara Sharmeen; Gregory van der Kroft; Pavel Strnad; Tom Florian Ulmer; Peter Isfort; Philipp Bruners; Georg Lurje; Ulf Peter Neumann Journal: World J Surg Oncol Date: 2020-06-24 Impact factor: 2.754
Authors: Nadja Lehwald-Tywuschik; Sascha Vaghiri; Jan Schulte Am Esch; Salman Alaghmand; Yan Klosterkemper; Lars Schimmöller; Anja Lachenmayer; Hany Ashmawy; Andreas Krieg; Stefan A Topp; Alexander Rehders; Wolfram Trudo Knoefel Journal: BMC Surg Date: 2020-04-06 Impact factor: 2.102